Wooters, T., Smith, A., Pivavarchyk, M., Siripurapu, K., McIntosh, J., Zhang, Z., … Dwoskin, L. (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Smith, A., Pivavarchyk, M., Wooters, T., Zhang, Z., Zheng, G., McIntosh, J., … Dwoskin, L. (2010). Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 80(3), 402-9. https://doi.org/10.1016/j.bcp.2010.03.018 (Original work published 2010)

Dwoskin, L., Wooters, T., Sumithran, S., Siripurapu, K., Joyce, B., Lockman, P., … Bardo, M. (2008). N,N’-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal of Pharmacology and Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630

Beckmann, J., Meyer, A., Pivavarchyk, M., Horton, D., Zheng, G., Smith, A., … Dwoskin, L. (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4